search
Back to results

Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts

Primary Purpose

Flat Wart

Status
Not yet recruiting
Phase
Phase 3
Locations
Mexico
Study Type
Interventional
Intervention
Isotretinoin capsules
Sponsored by
Centro Dermatológico Dr. Ladislao de la Pascua
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Flat Wart focused on measuring flat wart, isotretinoin, facial warts

Eligibility Criteria

18 Years - 40 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical and histological diagnosis of facial flats warts
  • More than 2 years with facial flat warts
  • Without response to 2 or more topical interventions (tretinoin, imiquimod, cryosurgery and 5-fluorouracil) or oral interventions (cimetidine or zinc sulfate)

Exclusion Criteria:

  • Have the following conditions:

    1. Hypercholesterolemia
    2. Hypertriglyceridemia
    3. Liver disease
    4. Renal disease
    5. Sjögren syndrome
    6. Pregnancy
    7. Lactation
    8. Depressive disorder
    9. Body mass index less than 18 points or higher than 25 points
    10. Contraindications for hormonal contraception or intrauterine device.

Sites / Locations

  • Centro Dermatológico "Dr. Ladislao de la Pascua"

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Active Comparator

Arm Label

Isotretinoin 10 mg/day

Isotretinoin 20 mg/day

Isotretinoin 30 mg/day

Arm Description

One capsule of isotretinoin 10 mg plus one capsule of placebo, per day during 12 weeks.

One capsule of isotretinoin 20 mg plus one capsule of placebo, per day during 12 weeks.

One capsule of isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks.

Outcomes

Primary Outcome Measures

Complete clearance
Proportion of participants with total remission of facial flat warts at the end of the intervention in the three arms of the clinical trial.
Incidence of serious adverse events
Proportion of participants that developed a serious side effect in the three arms during the clinical trial.

Secondary Outcome Measures

Quality of life index
Difference in the Dermatology Life Quality Index score at the end of the study, comparing with the basal score. The minimum score is 0 points and the maximum 30 points. A score higher than 10 points means that the patient's life is severely affected by melasma.
Adherence to intervention
Percentage of taken-doses of oral isotretinoin during the 12 weeks of the study.

Full Information

First Posted
February 27, 2020
Last Updated
February 28, 2020
Sponsor
Centro Dermatológico Dr. Ladislao de la Pascua
search

1. Study Identification

Unique Protocol Identification Number
NCT04290572
Brief Title
Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts
Official Title
Efficacy and Safety of Oral Isotretinoin 10 mg, 20 mg and 30 mg for the Treatment of Facial Recalcitrant Flat Warts at Centro Dermatológico "Dr. Ladislao de la Pascua": Randomized Double-blinded Clinical Trial of Three Arms
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Not yet recruiting
Study Start Date
March 15, 2020 (Anticipated)
Primary Completion Date
February 28, 2023 (Anticipated)
Study Completion Date
December 31, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centro Dermatológico Dr. Ladislao de la Pascua

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Randomized clinical trial to compare the efficacy of different doses of oral isotretinoin 10 mg/day, 20 mg/day and 30 mg/day during 12 weeks for the treatment of facial recalcitrant flat warts. The primary endpoint will be the proportion of participants with total remission of facial flat warts at the end of the intervention in the three arms of the clinical trial.
Detailed Description
The investigators will recruit 162 participants with facial recalcitrant flat warts and randomize to the following three arms of intervention: Arm 1: nne capsule of isotretinoin 10 mg plus one capsule of placebo, per day during 12 weeks; Arm 2: one capsule of isotretinoin 20 mg plus one capsule of placebo, per day during 12 weeks; and Arm 3: one capsule of isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks. The primary endpoints will be the proportion of participants with total remission of facial flat warts at the end of the intervention in the three arms of the clinical trial; and the incidence of side effects related to oral isotretinoin treatment among the 3 arms of treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Flat Wart
Keywords
flat wart, isotretinoin, facial warts

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Model Description
Randomized clinical trial of three-arms
Masking
ParticipantOutcomes Assessor
Masking Description
All the interventions will be similar in appearance and all the participants will take the same quantity of capsules.
Allocation
Randomized
Enrollment
162 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Isotretinoin 10 mg/day
Arm Type
Experimental
Arm Description
One capsule of isotretinoin 10 mg plus one capsule of placebo, per day during 12 weeks.
Arm Title
Isotretinoin 20 mg/day
Arm Type
Experimental
Arm Description
One capsule of isotretinoin 20 mg plus one capsule of placebo, per day during 12 weeks.
Arm Title
Isotretinoin 30 mg/day
Arm Type
Active Comparator
Arm Description
One capsule of isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks.
Intervention Type
Drug
Intervention Name(s)
Isotretinoin capsules
Other Intervention Name(s)
Oral retinoid
Intervention Description
Jelly capsules of isotretinoin
Primary Outcome Measure Information:
Title
Complete clearance
Description
Proportion of participants with total remission of facial flat warts at the end of the intervention in the three arms of the clinical trial.
Time Frame
12 weeks
Title
Incidence of serious adverse events
Description
Proportion of participants that developed a serious side effect in the three arms during the clinical trial.
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Quality of life index
Description
Difference in the Dermatology Life Quality Index score at the end of the study, comparing with the basal score. The minimum score is 0 points and the maximum 30 points. A score higher than 10 points means that the patient's life is severely affected by melasma.
Time Frame
12 weeks
Title
Adherence to intervention
Description
Percentage of taken-doses of oral isotretinoin during the 12 weeks of the study.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
40 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical and histological diagnosis of facial flats warts More than 2 years with facial flat warts Without response to 2 or more topical interventions (tretinoin, imiquimod, cryosurgery and 5-fluorouracil) or oral interventions (cimetidine or zinc sulfate) Exclusion Criteria: Have the following conditions: Hypercholesterolemia Hypertriglyceridemia Liver disease Renal disease Sjögren syndrome Pregnancy Lactation Depressive disorder Body mass index less than 18 points or higher than 25 points Contraindications for hormonal contraception or intrauterine device.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
María Guadalupe Olguín-García, M.D., MSc.
Phone
55387033
Ext
312
Email
olguingog@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Martha Alejandra Morales-Sánchez, M.D., MSc.
Phone
55387033
Ext
312
Email
mmoraless@sersalud.cdmx.gob.mx
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
María Guadalupe Olguín-García, M.D.,MSc.
Organizational Affiliation
Centro Dermatológico Dr. Ladislao de la Pascua
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centro Dermatológico "Dr. Ladislao de la Pascua"
City
Mexico City
ZIP/Postal Code
06780
Country
Mexico

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts

We'll reach out to this number within 24 hrs